Device Trial Radar · NCT05626504
Outcome Study of the Pipeline Embolization Device With Vantage Technology in Unruptured Aneurysms
Last checked: Nov 19, 2026Latest source record: Mar 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
50
Planned (sponsor's estimate)
Start
Oct 27, 2022
Primary completion
Mar 1, 2025
Study completion Mar 31, 2025
Sponsor
- Lead sponsor
- King's College Hospital NHS TrustAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 23, 2022
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this project the investigators study the safety and efficacy of the pipeline embolization device with vantage technology in treatment of unruptured brain aneurysms
Conditions
- Brain Aneurysm
- Intracranial Hemorrhages
- Stroke
Interventions
Pipeline Embolization Device with Vantage TechnologyDevice
Flow-diverter device occludes aneurysms through endoluminal reconstruction and remodelling of the parent artery.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate 30-day morbidity ratesTime frame: Done at 30 days post procedural
- Evaluate 30-day mortality ratesTime frame: Done at 30 days post procedural
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kings College Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.